Exelixis, Inc. (BIT:1EXEL)
Italy
· Delayed Price · Currency is EUR | Market Cap | 9.67B |
| Revenue (ttm) | 1.98B |
| Net Income (ttm) | 666.51M |
| Shares Out | n/a |
| EPS (ttm) | 2.37 |
| PE Ratio | 14.50 |
| Forward PE | 12.28 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3 |
| Average Volume | 35 |
| Open | 38.70 |
| Previous Close | 38.46 |
| Day's Range | 38.70 - 38.70 |
| 52-Week Range | 29.27 - 42.60 |
| Beta | n/a |
| RSI | 54.20 |
| Earnings Date | May 5, 2026 |
About Exelixis
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF recep... [Read more]
Financial Performance
In 2025, Exelixis's revenue was $2.32 billion, an increase of 6.98% compared to the previous year's $2.17 billion. Earnings were $782.57 million, an increase of 50.13%.
Financial numbers in USDNews
Exelixis to Release First Quarter 2026 Financial Results on Tuesday, May 5, 2026
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2026 financial results will be released on Tuesday, May 5, 2026 after the markets close. At 5:00 ...
Exelixis Transcript: Barclays 28th Annual Global Healthcare Conference
CABOMETYX drives strong sales and strategic focus in GI/GU oncology, with Zanzalintinib advancing in pivotal studies and a December PDUFA. Expansion into CRC and NET, disciplined BD, and innovative pipeline assets position the company for continued growth.
Exelixis Transcript: The Citizens Life Sciences Conference 2026
Revenue reached $2.123 billion with guidance for $2.4 billion in 2026, driven by RCC and NET launches. Zanza is positioned for a $5 billion+ opportunity with seven pivotal studies, while STELLAR-303 and -304 aim to set new standards in CRC and non-clear cell RCC.
Exelixis Transcript: Leerink Global Healthcare Conference 2026
Recent ASCO GU data in RCC showed PFS benefit but no significant OS improvement, influencing a shift toward sequential treatment strategies and highlighting the importance of quality of life and toxicity profiles. Key trials like LITESPARK-033 and STELLAR-304 aim to redefine standards in RCC, while STELLAR-303 in CRC demonstrated a survival advantage, supporting strong growth projections for 2026.
Exelixis Transcript: TD Cowen 46th Annual Health Care Conference
The discussion highlighted a strategic shift toward building multiple oncology franchises, with zanzalintinib poised for launch and pivotal trials underway. Strong commercial growth continues, especially in RCC and NET, while new combinations and indications are being pursued to sustain long-term relevance.
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in March: TD Cowen 46th...
Exelixis Earnings Call Transcript: Q4 2025
2025 saw robust revenue and net income growth, led by CABOMETYX's dominance in RCC and neuroendocrine tumors, and preparations for the launch of zanzalintinib in CRC. The company remains focused on expanding its oncology franchises, advancing pivotal trials, and maintaining strong capital allocation.
Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and fiscal year of 2025, provided an update on progress toward achieving key cor...
Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that its New Drug Application (NDA) for zanzalintinib, in combination with atezolizumab (Tecentriq®), has been accepted ...
Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its fourth quarter and fiscal year 2025 financial results will be released on Tuesday, February 10, 2026 after the ...
Exelixis Transcript: 44th Annual J.P. Morgan Healthcare Conference
The session highlighted a franchise-driven strategy in oncology, with strong 2025 financials and robust 2026 guidance. Growth is anchored by cabozantinib and zanzalitinib, supported by a multidimensional pipeline and disciplined capital allocation.
Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced its preliminary unaudited financial results for the fiscal year 2025, provided financial guidance for fiscal year 2026 a...
Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer
ALAMEDA, Calif. & AUSTIN, Texas--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) and Natera (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, today announced their collaboration ...
Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company's President and Chief Executive Officer, will provide a corporate overview...
See How Rare Bullish Inflows Lift Outliers Like Exelixis
Exelixis, Inc. (EXEL), an oncology-focused biopharmaceutical firm, is up 81% since a Big Money boost starting in 2021.
Exelixis Transcript: R&D Day 2025
Significant progress in advancing multi-franchise oncology platforms, with zanzalitinib emerging as a new backbone supported by positive pivotal trial data and regulatory filings. Multiple late-stage and early-stage assets target high unmet needs in RCC, CRC, and NETs, with strong commercial growth expected.
Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that it will webcast its virtual event, Exelixis 2025 R&D Day: Building Next-generation Oncology Franchises, on Wednesda...
Exelixis Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Strong Q3 revenue growth was driven by kidney cancer and a successful NET launch, with plans to expand the GI salesforce and pipeline. Zanzalintinib showed positive CRC data, with an NDA submission planned and new pivotal studies in CRC and RCC underway.
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in November: Guggenheim...
Exelixis Earnings Call Transcript: Q3 2025
Q3 2025 saw strong revenue and net income growth, led by Cabozantinib's leadership in RCC and rapid expansion in NETs, while Zanzalintinib achieved pivotal trial success in CRC. Guidance was raised, R&D expenses lowered, and a new $750M share repurchase was authorized.
Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2025, provided an update on progress toward achieving key corporate objectives...
Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2025 financial results will be released on Tuesday, November 4, 2025 after the markets close. At ...
Exelixis Stock Falls After Phase 3 Colorectal Cancer Trial Shows Mixed Results
Exelixis Inc. (NASDAQ:EXEL) stock is trading lower on Monday after the company shared detailed results from the STELLAR-303 Phase 3 trial.
Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The Lancet
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced detailed results from STELLAR-303, a global phase 3 pivotal trial evaluating zanzalintinib in combination with atezolizu...
Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the CABINET phase 3 pivotal trial evaluating CABOMETYX® (cabozantinib) versus placeb...